This article summarizes published peptide research. All content is presented for research reference only and is not intended as medical advice or guidance for personal peptide use. Products referenced are research compounds — not for human consumption, diagnostic or therapeutic application.

The problem with standard doses

The typical Tirzepatide titration scheme: 2.5 mg month one, 5 mg month two, 7.5, 10, then up to 15 mg. For Retatrutide: from 1 mg to 8-12 mg. At maximum doses, patients lose 15-25 percent of body weight over 12-18 months. Impressive numbers, but a nuance hides behind them.

With rapid weight loss (more than 2 pounds per week), a significant portion comes from muscle mass. In the SURMOUNT-1 trial, participants on Tirzepatide 15 mg lost an average of 22.5 percent of body weight, but up to 39 percent of that was lean mass. For someone who lost 55 pounds, that means roughly 22 pounds of muscle and water.

Beyond muscle loss, high doses cause pronounced side effects: nausea, vomiting, diarrhea, constipation. Some patients must discontinue therapy due to intolerance. And after stopping, weight returns, often completely.

Dr. Koniver's approach: lower dose, greater benefit

Dr. Matt Koniver, MD, a functional and integrative medicine specialist, proposed an alternative approach to GLP-1 therapy. His philosophy: instead of maximum doses for maximum weight loss, use microdoses for optimal health.

Key principles of the Koniver protocol:

• Dose: 1/5 to 1/10 of the standard maximum
• Weight loss rate: no more than 2 pounds per week
• Focus: not just weight reduction but overall metabolic health improvement
• Duration: longer course but with sustainable results

Specific microdose numbers

For Tirzepatide:

• Standard maximum: 15 mg per week
• Koniver microdose: 1.5-3 mg per week
• Some patients receive 2.5 mg (minimum standard dose) every 10-14 days instead of weekly

For Retatrutide:

• Standard maximum: 8-12 mg per week
• Microdose: 1-2 mg per week

The Tirzepatide pen and Retatrutide pen from Peptex enable precise dosing for the microprotocol through calibrated delivery systems.

Why microdoses work

GLP-1 receptors are not limited to the pancreas and gut. They exist in the brain, heart, liver, and muscles. At microdoses, these receptors receive sufficient stimulus for therapeutic effect without the excessive stimulation that causes side effects.

At the cellular level, several things happen:

• Insulin sensitivity improves at doses well below those needed for appetite suppression
• Inflammatory markers (hsCRP, IL-6) decrease even on minimal doses
• Neuroprotective GLP-1 effects in the brain (memory, neuroplasticity) are realized at low concentrations
• Cardioprotection (reduced MACE risk) begins at small doses

Muscle mass preservation

The primary advantage of microdosing is minimal muscle loss. At a weight loss rate of 1-2 pounds per week, the body has time to adapt and directs the deficit predominantly toward fat stores. The lost-fat-to-muscle ratio shifts from 60:40 (high doses, rapid loss) to 85:15 or better.

This is especially critical for people over 40, who are already losing muscle mass with age (sarcopenia). Losing an additional 20 pounds of muscle on aggressive GLP-1 therapy means accelerating sarcopenia by years.

With microdosing, the caloric deficit is moderate (300-500 kcal per day instead of 1000 plus), and the body compensates more easily from fat without touching muscle. Add resistance training and adequate protein, and muscle loss becomes minimal.

Cognitive improvements

An unexpected bonus of GLP-1 microdosing is cognitive improvement. GLP-1 receptors in the hippocampus and prefrontal cortex participate in memory formation and decision-making. On microdoses, patients frequently report:

• Improved mental clarity
• Reduced brain fog
• Better focus and attention
• Reduced impulsivity in decision-making (including food decisions)

These effects occur at standard doses too, but on microdoses they are more noticeable because they are not masked by nausea and general discomfort.

Anti-inflammatory effects

Chronic inflammation is a background process that accelerates aging, worsens metabolism, and increases disease risk. GLP-1 peptides possess pronounced anti-inflammatory action through several mechanisms:

• Reduction of CRP (C-reactive protein)
• NF-kappaB suppression in immune cells
• Reduced oxidative stress
• Improved vascular endothelial function

Microdoses are sufficient to realize these effects. Koniver views GLP-1 not so much as a weight loss tool but as an anti-inflammatory and metabolic optimizer. Weight loss is a side effect of metabolic optimization.

Combination with other peptides

The GLP-1 microprotocol combines well with other molecules because low doses do not overload the body:

• NAD+ for cellular energy support on a moderate deficit. NAD+ pen for convenience
• GHK-Cu to prevent skin laxity during slow weight loss. On microdoses weight loss is slower and skin adapts better, but collagen support adds value
• Ipamorelin for nighttime GH stimulation to protect muscle. Synergy with moderate deficit

Who the microprotocol suits

• People needing to lose 10-30 pounds (not 70 plus) where microdoses suffice
• Those who value muscle mass and do not want to lose it
• People over 40-50 for whom sarcopenia is a real risk
• Those who cannot tolerate standard doses due to side effects
• People interested in GLP-1 cognitive and anti-inflammatory effects, not just weight loss
• Athletes who need to maintain performance

Expected timeline and results

• Weeks 1-2: appetite reduction minimal, but portion control improves
• Weeks 3-4: 2-4 pound loss, improved mental clarity
• Month 2: 6-8 pound loss, noticeable energy improvement
• Month 3: 10-15 pound loss, lab improvements (HbA1c, triglycerides, CRP)
• Month 6: 20-30 pound loss, significant metabolic marker improvement
• Month 12: target weight reached, preparation for maintenance phase

Yes, this is slower than the standard protocol. But results are more sustainable, muscle is preserved, side effects are minimal, and health benefits are the same or even greater.

To transition to the microprotocol or for dosing guidance, reach out to support.